Literature DB >> 16049291

Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.

H Sartelet1, E Lagonotte, M Lorenzato, I Duval, C Lechki, C Rigaud, J Cucherousset, A Durlach, O Graesslin, P Abboud, M Doco-Fenzy, C Quereux, B Costa, M Polette, J-N Munck, P Birembaut.   

Abstract

BACKGROUND: HER-2 amplification is an important prognostic biomarker and treatment determinant in breast carcinoma. AIMS: To correlate immunocytochemical (ICC) expression of HER-2 and gene amplification determined by chromogenic in situ hybridisation (CISH) using liquid based cytology (LBC) with immunohistochemistry (IHC) and CISH using histological samples of the same breast carcinomas.
METHODS: Frozen sections and cytobrushings of 103 breast carcinomas were analysed. Four techniques were performed on each tumour: two on LBC samples (ICC, and CISH, both graded as positive, indeterminate, or negative) and two on histological samples (IHC and CISH). Two cell lines (MCF-7, negative; BT 474, positive) were used as controls for cytological analysis. A complementary fluorescence in situ hybridisation technique was carried out in histological samples with low amplification (4-10 dots/nucleus).
RESULTS: Interobserver agreement for the four techniques calculated by the kappa coefficient indicated a substantial agreement. Nine cases failed in cytology because of poor cellularity. Among 94 cases, 19 were amplified; 73, 12, and 9 tumours were scored 0 or 1+, 2+, and 3+, respectively by IHC and 75, 13, and 6, respectively, by ICC. CISH found no amplification in 72 tumours. Correlations between the IHC and CISH results in the histological and cytological samples were always significant.
CONCLUSIONS: Her-2 status could be determined in LBC samples and correlated well with reference histological methods using in situ hybridisation. ICC was less reliable because of the presence of the cytoplasmic membrane. However, these results should be confirmed by a large multicentre study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049291      PMCID: PMC1770887          DOI: 10.1136/jcp.2004.024224

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  ThinPrep vs. conventional smear cytologic preparations in analyzing fine-needle aspiration specimens from palpable breast masses.

Authors:  C V Biscotti; J H Shorie; T L Gramlich; K A Easley
Journal:  Diagn Cytopathol       Date:  1999-08       Impact factor: 1.582

2.  HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.

Authors:  J G Moore; V To; S J Patel; N Sneige
Journal:  Diagn Cytopathol       Date:  2000-11       Impact factor: 1.582

3.  Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides.

Authors:  M Skacel; J D Pettay; E K Tsiftsakis; G W Procop; C V Biscotti; R R Tubbs
Journal:  Anal Quant Cytol Histol       Date:  2001-12       Impact factor: 0.302

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Authors:  N Harbeck; J S Ross; S Yurdseven; P Dettmar; M Pölcher; W Kuhn; K Ulm; H Graeff; M Schmitt
Journal:  Int J Oncol       Date:  1999-04       Impact factor: 5.650

6.  Quantification of HER2 oncoprotein in fine-needle aspirates of the breast.

Authors:  J T Wu; P Zhang; J S Bentz
Journal:  Ann Clin Lab Sci       Date:  2000-01       Impact factor: 1.256

7.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

Authors:  M Tanner; D Gancberg; A Di Leo; D Larsimont; G Rouas; M J Piccart; J Isola
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

8.  c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples.

Authors:  F Farabegoli; C Ceccarelli; D Santini; N Baldini; M Taffurelli; D Marrano; D Treré; M Derenzini
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

9.  Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas.

Authors:  Rita Nizzoli; Cecilia Bozzetti; Pellegrino Crafa; Nadia Naldi; Annamaria Guazzi; Beatrice Di Blasio; Roberta Camisa; Stefano Cascinu
Journal:  Diagn Cytopathol       Date:  2003-03       Impact factor: 1.582

10.  Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.

Authors:  Nadia Dandachi; Otto Dietze; Cornelia Hauser-Kronberger
Journal:  Lab Invest       Date:  2002-08       Impact factor: 5.662

View more
  6 in total

1.  Testing for her2 in breast cancer: current pathology challenges faced in Canada.

Authors:  W Hanna; P Barnes; R Berendt; M Chang; A Magliocco; A M Mulligan; H Rees; N Miller; L Elavathil; B Gilks; N Pettigrew; D Pilavdzic; S Sengupta
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

2.  Introduction and utility of liquid-based cytology on aspiration biopsy of peripheral nodular lesions of the lung.

Authors:  Johji Imura; Kaori Abe; Yoshiaki Uchida; Masaharu Shibata; Kazue Tsunematsu; Motohiro Sathoh; Shigeharu Miwa; Takahiko Nakajima; Kazuhiro Nomoto; Shinichi Hayashi; Koichi Tsuneyama
Journal:  Oncol Lett       Date:  2013-12-17       Impact factor: 2.967

Review 3.  Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.

Authors:  F E Rosa; R M Santos; S R Rogatto; M A C Domingues
Journal:  Braz J Med Biol Res       Date:  2013-03-19       Impact factor: 2.590

4.  RefCNV: Identification of Gene-Based Copy Number Variants Using Whole Exome Sequencing.

Authors:  Lun-Ching Chang; Biswajit Das; Chih-Jian Lih; Han Si; Corinne E Camalier; Paul M McGregor; Eric Polley
Journal:  Cancer Inform       Date:  2016-04-27

5.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

6.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.